TITLE

Lilly deal could set the bar for disclosures

AUTHOR(S)
Arnold, Matthew
PUB. DATE
November 2008
SOURCE
Medical Marketing & Media;Nov2008, Vol. 43 Issue 11, p34
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the settlement deal of Eli Lilly & Co. with the U.S. over off-label Zyprexa drug marketing. The deal can lead to disclosure of reporting requirements in future agreements with states. It includes provisions governing promotional activities, dissemination of medical information, and stipulate areas which are off limits to sales. The agreement prohibits the company from promoting off-label uses of the drug and bars sales.
ACCESSION #
35131888

 

Related Articles

  • Three products gild the Lilly bottom line, but where are their successors? Seiden, Carl // Medical Marketing & Media;Jun99, Vol. 34 Issue 6, p68 

    Focuses on the marketing plans of Eli Lilly & Co. for its three drugs products with the goal of boosting earnings for 1999. Optimism for the company's marketing outlook for Prozac; Success of the company in making product comparisons with its Zyprexa anti-psychotic drug; Promotion campaign for...

  • Cialis postponed until 2003.  // Drug Store News;5/20/2002, Vol. 24 Issue 7, p8 

    Announces the postponement of the marketing of impotence drug Cialis manufactured by Eli Lilly.

  • Ell Lilly puts faith in drug pipeline. Wall, J. K. // Indianapolis Business Journal;12/27/2010, Vol. 31 Issue 44, p13A 

    The article reports on the belief of Eli Lilly & Co. on the launch of its drug pipeline to increase sales in international markets, while cutting expenses by reducing jobs in which it eliminated more than 2,700 jobs on a way to 5,500 positions by the end of 2011.

  • Lilly, too, wrestling with probe by feds. Andrews, Greg // Indianapolis Business Journal;6/23/2003, Vol. 24 Issue 15, p4 

    Reports on the governmental investigation on Eli Lilly and Co. for marketing the Evista drug in Indianapolis, Indiana. Consequence from the guilty plea of Guidant Corp. to felony cases; Criminal penalties for illegal promotion of drug with the U.S. Food and Drug Administration approval;...

  • Prozac Nación. Estevez, Matthew; Brown, Greg // Latin Trade (English);Mar2003, Vol. 11 Issue 3, p27 

    Focuses on the efforts of U.S. drug manufacturer Eli Lilly to market its anti-depressant Prozac in the Andean region. Information on the sales of Prozac in 2002; Reasons of Eli Lilly for targeting the region; Social factors that may affect the acceptance of the drug in the region.

  • Needy market awaits Lilly's new sepsis drug Xigris.  // Medical Marketing & Media;Dec2001, Vol. 36 Issue 12, p16 

    Reports on the expected high demand for the drug Xigris from Eli Lilly & Co. in the U.S. Approval for use against sepsis; Statistics on death caused by sepsis.

  • DDR on DTC. Dick-Rath, Deborah // Medical Marketing & Media;Oct2012, Vol. 47 Issue 10, p26 

    In this article the author discusses the continued commitment of Eli Lilly & Co. to brand its erectile dysfunction (ED) drug Cialis as only for couples.

  • Lilly resolves multi-state investigation of Zyprexa.  // PharmaWatch: CNS;Nov2008, Vol. 7 Issue 11, p10 

    The article reports on the multi-state investigation settled by Eli Lilly and Co. with the 32 states in the U.S. that relates to the marketing and sales of its drug Zyprexa. The company said that they will pay $62 million even there is no finding that they violate any provision of the state...

  • Lilly, Alkermes in Deal.  // Chemical Market Reporter;2/25/2002, Vol. 261 Issue 8, p36 

    Reports on the contract signed by Eli Lilly and Co. with Alkermes Inc. Investment of Eli Lilly on Alkermes; Net loss posted by Alkermes for the period that ended December 31, 2001.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics